TRUMF:OTO-Terumo Corp. (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 18.296

Change

+0.58 (+3.25)%

Market Cap

USD 12.70B

Volume

3.20K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-07 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

+2.10 (+0.86%)

USD 110.71B
ESLOY Essilor International SA

+0.63 (+0.52%)

USD 110.71B
HOCPF HOYA Corporation

-0.72 (-0.59%)

USD 43.69B
HOCPY Hoya Corp

+1.57 (+1.25%)

USD 43.69B
CLPBY Coloplast A

+0.05 (+0.46%)

USD 30.06B
CLPBF Coloplast A/S

N/A

USD 24.49B
SAUHF Straumann Holding AG

+7.79 (+6.26%)

USD 19.74B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 19.12B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 18.97B
OCPNF Olympus Corporation

N/A

USD 17.48B

ETFs Containing TRUMF

DXJH 0.00 % 0.48 %

N/A

N/A
CNKY:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

+62.00 (+2.04%)

USD 50.44B
XDJP:LSE Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+6.50 (+2.04%)

N/A
SXRZ:F iShares VII PLC - iShares.. 0.00 % 0.00 %

+1.45 (+2.04%)

USD 52.42B
EXX7:XETRA iShares Nikkei 225 UCITS .. 0.00 % 0.00 %

+0.06 (+2.04%)

USD 28.25B
SXRZ:XETRA iShares VII PLC - iShares.. 0.00 % 0.00 %

+0.45 (+2.04%)

USD 58.15B
XDJE:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+0.07 (+2.04%)

USD 0.03B
XDJP:XETRA Xtrackers Nikkei 225 UCIT.. 0.00 % 0.00 %

+0.06 (+2.04%)

USD 157.79B
1329:TSE iShares Core Nikkei 225 E.. 0.00 % 0.00 %

+730.00 (+2.04%)

USD 1,529.93B
1330:TSE Nikko Nikkei 225 Listed 0.00 % 0.00 %

+780.00 (+2.04%)

USD 5,423.56B
1369:TSE DIAM Nikkei 225 0.00 % 0.00 %

+700.00 (+2.04%)

USD 451.27B
1578:TSE Listed Index Fund Nikkei .. 0.00 % 0.00 %

+40.00 (+2.04%)

USD 12.13B
1397:TSE SMDS SMDAM NIKKEI225 ETF 0.00 % 0.00 %

+810.00 (+2.04%)

USD 195.63B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.56% 19% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.56% 19% F 19% F
Trailing 12 Months  
Capital Gain 10.64% 80% B- 67% D+
Dividend Return 1.54% 63% D 16% F
Total Return 12.18% 80% B- 65% D
Trailing 5 Years  
Capital Gain 3.72% 63% D 67% D+
Dividend Return 5.43% 21% F 13% F
Total Return 9.15% 65% D 62% D
Average Annual (5 Year Horizon)  
Capital Gain -1.04% 40% F 35% F
Dividend Return 36.92% 78% C+ 71% C-
Total Return 37.96% 100% F 95% A
Risk Return Profile  
Volatility (Standard Deviation) 52.61% 43% F 50% F
Risk Adjusted Return 70.18% 97% N/A 93% A
Market Capitalization 12.70B 90% A- 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.